<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03991650</url>
  </required_header>
  <id_info>
    <org_study_id>humanITcare: Remote</org_study_id>
    <nct_id>NCT03991650</nct_id>
  </id_info>
  <brief_title>Monitoring Telemedicine Platform in Patients With Anxiety Symptoms and Alcohol Use Disorder</brief_title>
  <acronym>REMOTE</acronym>
  <official_title>REMOTE: Monitoring Telemedicine Platform in Patients With Anxiety Symptoms and Alcohol Use Disorder: Smartphone and Wearable Sensors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>humanITcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Institute of Innovation and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>humanITcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to analyze the physiological patterns of two groups of
      patients, one control and one with anxiety disorder and alcoholic abuse disorder using sensor
      data from mobile devices and wearables. This data will be compared to the data presented by
      three clinical questionnaires: State-trait Anxiety Inventory (STAI), the Alcohol Use
      Disorders Identification Test (AUDIT), and the Beck's Depression Inventory (BDI-II) in order
      to determine the feasibility of remote collected data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to analyze the physiological patterns of two groups of
      patients, one control and one with anxiety disorder and alcoholic abuse disorder using sensor
      data from mobile devices and wearables. This data, collected by sensors, will be compared to
      the data presented by three clinical questionnaires: State-trait Anxiety Inventory (STAI),
      the Alcohol Use Disorders Identification Test (AUDIT), and the Beck's Depression Inventory
      (BDI-II) in order to determine the feasibility of using remote collected data in routine
      clinical practice. Furthermore, patient satisfaction with the app will be evaluated after the
      data collection phase.

      This is a unicentric, case-controlled, longitudinal, evaluational, national study with two
      groups, one control of healthy individuals without symptoms of anxiety or depression, and
      another experimental group in which participants fulfill the given selection criteria for the
      trial. There are a total of 60 participants split evenly between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Change in Self-reported Anxiety symptoms assessed with the State-Trait Anxiety Inventory (STAI)</measure>
    <time_frame>One month, questionnaire taken 4 times (1/week)</time_frame>
    <description>Taken through the application &quot;Ushine&quot;. Participants receive STAI scores ranging from 0-60, 0 being lowest amount of symptoms, and 60 being the greatest amount of symptoms, which are then transformed into percentiles according to age and sex.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep pattern</measure>
    <time_frame>One month</time_frame>
    <description>Monitoring of circadian rhythm using a motion sensor Fitbit and cardiac activity sensor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>REM sleep time</measure>
    <time_frame>One month</time_frame>
    <description>monitoring of REM sleep patterns using a motion sensor Fitbit and cardiac activity sensor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>One month</time_frame>
    <description>monitoring of heart rate using Fitbit sensor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Step count</measure>
    <time_frame>One month</time_frame>
    <description>Monitoring of daily step count using motion sensor FitBit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distance travelled</measure>
    <time_frame>One month</time_frame>
    <description>Monitoring of distance travelled using GPS phone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mobile device usage</measure>
    <time_frame>One month</time_frame>
    <description>Monitoring how often the patient's mobile device is used, determined by tracking the presence of a signal from their device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sociability (number of incoming an outgoing calls and text messages)</measure>
    <time_frame>One month</time_frame>
    <description>The number of incoming and outgoing calls and text messages will be monitored using the UShine app algorithm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Self-reported Depression symptoms assessed with the Beck's Depression Inventory (BDI-II)</measure>
    <time_frame>One month, questionnaire taken 4 times (1/week)</time_frame>
    <description>Taken through the application &quot;Ushine&quot;. Participants receive BDI-II scores ranging from 1-63, with a score of 0-13 indicating minimal depression, 14-19 indicating mild depression, 20-28 indicating moderate depression, and 29-63 indicating severe depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Self-reported Alcohol Abuse Symptoms assesed with the Alcohol Use Disorders Identification Test (AUDIT)</measure>
    <time_frame>One month, questionnaire taken 4 times (1/week)</time_frame>
    <description>Taken through the application &quot;Ushine&quot;. Participants receive AUDIT scores ranging from 0-40. A score of 8 or more is associated with harmful or hazardous drinking, a score of 13 or more in women, and 15 or more in men, is likely to indicate alcohol dependence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Usability of the mobile application</measure>
    <time_frame>One month</time_frame>
    <description>Ease of usability of the mobile applications by participants will be scaled using the System Usability Scale (SUS). Final scores range from 0-100. A score of 51 or under means the system has serious faults in usability, a score of 68 means the system usability is about average, and a score of 80.3 or higher means the system usability is considered appreciable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with the application</measure>
    <time_frame>One month</time_frame>
    <description>Participants' satisfaction with the Ushine application will be scaled using the Post-Study Usability Questionnaire (PSSUQ). Scores range from 0-100, 0 being least satisfactory and 100 being the most satisfactory. The PSSUQ has 3 sub-scores representing system usefulness, information quality, and interface quality, also scaled from 0-100. In all score sets, 0 is considered the least satisfactory and 100 is considered the most satisfactory.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anxiety Disorders</condition>
  <condition>Alcohol Use Disorder</condition>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>n=30 healthy participants will be recruited using social networks and leaflets of information distributed by the research team at the Hospital Clin√≠c de Barcelona.
The participants will be monitored over the course of one month using the humanITcare app &quot;U-Shine,&quot; which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants' data will also be monitored with a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <description>The recruitment process will be carried out in patients of external consultations and the day hospital of the Addictions Unit at the Hospital Clinic of Barcelona.
n=30 patients with Anxiety and Alcohol Use Disorder.
The participants will be monitored over the course of one month using the humanITcare app &quot;U-Shine,&quot; which will track participant's sociability, device usage, and location frequency using mobile sensors. Participants will also be monitored using a FitBit device to track sleep schedules, heart rate, and step count. During the weekly follow-up, they will have to complete the three clinical questionnaires taken at the initial visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Monitoring with a device</intervention_name>
    <description>Participants will be monitored by an App.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        There will be a sample n = 60, with 30 healthy control subjects and 30 afflicted
        experimental subjects.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years of age.

          -  Alcohol use disorder (DSM 5) as main substance.

          -  Anxiety (STAI &gt; percentile 33) and, if depressive symptoms, not clinically relevant as
             to accomplish DSM5 diagnostic criteria for mood disorders (major depressive disorder,
             bipolar disorder‚Ä¶).

          -  Having a mobile phone compatible with Android.

          -  Sign informed consent.

        Exclusion Criteria:

          -  Mood disorder diagnoses (DSM5).

          -  Cognitive deficits that prevent the participation.

          -  Active intake of other substances (except for nicotine).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoni Gual, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Addictions Unit. Hospital Cl√≠nic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elsa Caballeria</last_name>
    <role>Study Chair</role>
    <affiliation>Clinic Foundation for Biomedical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo Lopez-Pelayo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Addictions Unit, Hospital Cl√≠nic de Barcelona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nuria Pastor Hernandez, MSc</last_name>
    <role>Study Director</role>
    <affiliation>humanITcare, FollowHealth SL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Unai Sanchez Luque, MSc</last_name>
    <role>Study Director</role>
    <affiliation>humanITcare, FollowHealth SL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Katayoun Khalilian</last_name>
    <role>Study Chair</role>
    <affiliation>humanITcare, University of Texas at Austin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nuria Pastor Hernandez, MSc</last_name>
    <phone>+34 628994983</phone>
    <email>nuria.pastor@humanitcare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Unai S√°nchez Luque, MSc</last_name>
    <phone>+34 620248183</phone>
    <email>unai.sanchez@humanitcare.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospitcal Cl√≠nic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.who.int/news-room/fact-sheets/detail/alcohol</url>
    <description>World Health Organization. Global Status Report on Alcohol and Health (2018).</description>
  </link>
  <link>
    <url>https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf</url>
    <description>World Health Organization. Mental depression and other common disorders: Global health estimates (2017).</description>
  </link>
  <reference>
    <citation>Alonso J, Liu Z, Evans-Lacko S, Sadikova E, Sampson N, Chatterji S, Abdulmalik J, Aguilar-Gaxiola S, Al-Hamzawi A, Andrade LH, Bruffaerts R, Cardoso G, Cia A, Florescu S, de Girolamo G, Gureje O, Haro JM, He Y, de Jonge P, Karam EG, Kawakami N, Kovess-Masfety V, Lee S, Levinson D, Medina-Mora ME, Navarro-Mateu F, Pennell BE, Piazza M, Posada-Villa J, Ten Have M, Zarkov Z, Kessler RC, Thornicroft G; WHO World Mental Health Survey Collaborators. Treatment gap for anxiety disorders is global: Results of the World Mental Health Surveys in 21 countries. Depress Anxiety. 2018 Mar;35(3):195-208. doi: 10.1002/da.22711. Epub 2018 Jan 22.</citation>
    <PMID>29356216</PMID>
  </reference>
  <reference>
    <citation>Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, J√∂nsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011 Sep;21(9):655-79. doi: 10.1016/j.euroneuro.2011.07.018. Review.</citation>
    <PMID>21896369</PMID>
  </reference>
  <reference>
    <citation>Barrio P, Ortega L, L√≥pez H, Gual A. Self-management and Shared Decision-Making in Alcohol Dependence via a Mobile App: a Pilot Study. Int J Behav Med. 2017 Oct;24(5):722-727. doi: 10.1007/s12529-017-9643-6.</citation>
    <PMID>28236288</PMID>
  </reference>
  <reference>
    <citation>Gustafson DH, McTavish FM, Chih MY, Atwood AK, Johnson RA, Boyle MG, Levy MS, Driscoll H, Chisholm SM, Dillenburg L, Isham A, Shah D. A smartphone application to support recovery from alcoholism: a randomized clinical trial. JAMA Psychiatry. 2014 May;71(5):566-72. doi: 10.1001/jamapsychiatry.2013.4642.</citation>
    <PMID>24671165</PMID>
  </reference>
  <reference>
    <citation>Reddy MS. Depression: the disorder and the burden. Indian J Psychol Med. 2010 Jan;32(1):1-2. doi: 10.4103/0253-7176.70510.</citation>
    <PMID>21799550</PMID>
  </reference>
  <reference>
    <citation>Menger V, Spruit M, Hagoort K, Scheepers F. Transitioning to a Data Driven Mental Health Practice: Collaborative Expert Sessions for Knowledge and Hypothesis Finding. Comput Math Methods Med. 2016;2016:9089321. doi: 10.1155/2016/9089321. Epub 2016 Aug 17.</citation>
    <PMID>27630736</PMID>
  </reference>
  <reference>
    <citation>Hsin H, Torous J, Roberts L. An Adjuvant Role for Mobile Health in Psychiatry. JAMA Psychiatry. 2016 Feb;73(2):103-4. doi: 10.1001/jamapsychiatry.2015.2839. Review.</citation>
    <PMID>26747695</PMID>
  </reference>
  <reference>
    <citation>Insel TR. Digital Phenotyping: Technology for a New Science of Behavior. JAMA. 2017 Oct 3;318(13):1215-1216. doi: 10.1001/jama.2017.11295.</citation>
    <PMID>28973224</PMID>
  </reference>
  <reference>
    <citation>Bernert RA, Hom MA, Iwata NG, Joiner TE. Objectively Assessed Sleep Variability as an Acute Warning Sign of Suicidal Ideation in a Longitudinal Evaluation of Young Adults at High Suicide Risk. J Clin Psychiatry. 2017 Jun;78(6):e678-e687. doi: 10.4088/JCP.16m11193.</citation>
    <PMID>28682534</PMID>
  </reference>
  <reference>
    <citation>Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015 Sep;17(3):327-35.</citation>
    <PMID>26487813</PMID>
  </reference>
  <reference>
    <citation>Saeb S, Zhang M, Karr CJ, Schueller SM, Corden ME, Kording KP, Mohr DC. Mobile Phone Sensor Correlates of Depressive Symptom Severity in Daily-Life Behavior: An Exploratory Study. J Med Internet Res. 2015 Jul 15;17(7):e175. doi: 10.2196/jmir.4273.</citation>
    <PMID>26180009</PMID>
  </reference>
  <reference>
    <citation>Saeb S, Lattie EG, Kording KP, Mohr DC. Mobile Phone Detection of Semantic Location and Its Relationship to Depression and Anxiety. JMIR Mhealth Uhealth. 2017 Aug 10;5(8):e112. doi: 10.2196/mhealth.7297.</citation>
    <PMID>28798010</PMID>
  </reference>
  <reference>
    <citation>Sano A, Taylor S, McHill AW, Phillips AJ, Barger LK, Klerman E, Picard R. Identifying Objective Physiological Markers and Modifiable Behaviors for Self-Reported Stress and Mental Health Status Using Wearable Sensors and Mobile Phones: Observational Study. J Med Internet Res. 2018 Jun 8;20(6):e210. doi: 10.2196/jmir.9410.</citation>
    <PMID>29884610</PMID>
  </reference>
  <reference>
    <citation>Torous J, Staples P, Shanahan M, Lin C, Peck P, Keshavan M, Onnela JP. Utilizing a Personal Smartphone Custom App to Assess the Patient Health Questionnaire-9 (PHQ-9) Depressive Symptoms in Patients With Major Depressive Disorder. JMIR Ment Health. 2015 Mar 24;2(1):e8. doi: 10.2196/mental.3889. eCollection 2015 Jan-Mar.</citation>
    <PMID>26543914</PMID>
  </reference>
  <reference>
    <citation>Onnela JP, Rauch SL. Harnessing Smartphone-Based Digital Phenotyping to Enhance Behavioral and Mental Health. Neuropsychopharmacology. 2016 Jun;41(7):1691-6. doi: 10.1038/npp.2016.7. Epub 2016 Jan 28.</citation>
    <PMID>26818126</PMID>
  </reference>
  <reference>
    <citation>Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Rep. 2016 Sep;17(9):1245-9. doi: 10.15252/embr.201642951. Epub 2016 Aug 4.</citation>
    <PMID>27491723</PMID>
  </reference>
  <reference>
    <citation>Ghandeharioun, A., Fedor, S., Sangermano, L., Ionescu, D., Alpert, J., Dale, C., ... &amp; Picard, R. (2017, October). Objective assessment of depressive symptoms with machine learning and wearable sensors data. In Affective Computing and Intelligent Interaction (ACII), 2017 Seventh International Conference on (pp. 325-332). IEEE.</citation>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wearable</keyword>
  <keyword>sensor</keyword>
  <keyword>anxiety</keyword>
  <keyword>monitoring</keyword>
  <keyword>ehealth</keyword>
  <keyword>Alcohol Use Disorder</keyword>
  <keyword>depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data sets that underlie results in the final study report will be available for sharing.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be available by the estimated date of September 2019, when study results are expected to be published</ipd_time_frame>
    <ipd_access_criteria>Participants can access their own individual data records, only hospital researchers can access the aggregated data sets.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

